SMMT•benzinga•May 30, 2025 at 10:29 AM

Summit Therapeutics Announced Topline Results From The Phase 3 Trial HARMONi Evaluating Ivonescimab, Met The Progression-free Survival Primary Endpoint And Showed A Positive Trend In The Other Primary Endpoint, Overall Survival

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 30, 2025 by benzinga